The infrastructure of the global pharmaceutical supply chain is governed by a highly scrutinized, multi-layered regulatory matrix. Within this institutional ecosystem, the lifecycle of controlled substances—ranging from primary chemical synthesis down to the ultimate clinical utilization or permanent destruction—is monitored to eliminate leakage. When controlled substance inventory expires, becomes contaminated, or faces commercial recall, it […]